Combined anti-VEGF and anti–CTLA-4 therapy elicits humoral immunity to galectin-1 which is associated with favorable clinical outcomes

X Wu, J Li, EM Connolly, X Liao, J Ouyang… - Cancer immunology …, 2017 - AACR
X Wu, J Li, EM Connolly, X Liao, J Ouyang, A Giobbie-Hurder, D Lawrence, D McDermott…
Cancer immunology research, 2017AACR
The combination of anti-VEGF blockade (bevacizumab) with immune checkpoint anti–CTLA-
4 blockade (ipilimumab) in a phase I study showed tumor endothelial activation and immune
cell infiltration that were associated with favorable clinical outcomes in patients with
metastatic melanoma. To identify potential immune targets responsible for these
observations, posttreatment plasma from long-term responding patients were used to screen
human protein arrays. We reported that ipilimumab plus bevacizumab therapy elicited …
Abstract
The combination of anti-VEGF blockade (bevacizumab) with immune checkpoint anti–CTLA-4 blockade (ipilimumab) in a phase I study showed tumor endothelial activation and immune cell infiltration that were associated with favorable clinical outcomes in patients with metastatic melanoma. To identify potential immune targets responsible for these observations, posttreatment plasma from long-term responding patients were used to screen human protein arrays. We reported that ipilimumab plus bevacizumab therapy elicited humoral immune responses to galectin-1 (Gal-1), which exhibits protumor, proangiogenesis, and immunosuppressive activities in 37.2% of treated patients. Gal-1 antibodies purified from posttreatment plasma suppressed the binding of Gal-1 to CD45, a T-cell surface receptor that transduces apoptotic signals upon binding to extracellular Gal-1. Antibody responses to Gal-1 were found more frequently in the group of patients with therapeutic responses and correlated with improved overall survival. In contrast, another subgroup of treated patients had increased circulating Gal-1 protein instead, and they had reduced overall survival. Our findings suggest that humoral immunity to Gal-1 may contribute to the efficacy of anti-VEGF and anti–CTLA-4 combination therapy. Gal-1 may offer an additional therapeutic target linking anti-angiogenesis and immune checkpoint blockade. Cancer Immunol Res; 5(6); 446–54. ©2017 AACR.
AACR